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Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients
present with its actual clinical manifestations. The most common findings are increased red cell
mass and an increased leukocyte count with decreased erythropoietin. We present a case
where there was a delay in the diagnosis of polycythemia because of menorrhagia in the past.
On admission, the patient presented with elevated red and white blood cell counts, erythropoi-
etin was low, and polycythemia was then suspected. A bcr-abl test was performed to rule out
chronic myelogenous leukemia. JAK2 mutation was positive, and the patient was diagnosed
with polycythemia vera.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Polycythemia vera (PV) is one of the chronic myeloprolifer-
ative disease characterized by increased red cell mass on
normal hemoglobin oxygen saturation, and may have an
elevated white cell count and an elevated platelet count.
Low erythropoietin levels and JAK2 mutation are highlyspecific for PV. Here we present a case of a 52-year-old
female who had a history of severe iron deficiency anemia
due to menorrhagia from fibroids and was diagnosed with
PV only after having amenorrhea for 8 months.Case report
A 52-year-old African-American female presented to a hos-
pital in March 2016 with shortness of breath and cough for
3–4 days. She also complained of Grade 3 dyspnea. She
denied any history of pruritus, dizziness, vasomotor
symptoms, fatigue, and paresthesia. Past medical historyncol Stem
2 S. Kambali, A. Tajwas significant for chronic obstructive lung disease, obesity,
diabetes, and peptic ulcer disease. She had a history of ane-
mia due to severe menorrhagia from fibroids. She has been
amenorrheic for 8 months now and was placed on oral iron
therapy twice a day for anemia. Her social history was pos-
itive for smoking with a 20 pack year index, but there was no
history of alcohol or illicit drug use.
On physical examination the vital signs were stable; the
left eye showed subconjunctival congestion. Chest, cardio-
vascular, abdominal, and neurological examinations were
normal. Laboratory data on admission are given in Table 1.
The patient was suspected to have secondary poly-
cythemia. Her arterial blood gas (ABG) showed the follow-
ing: pH, 7.33 (7.35–7.45); pCO2, 45 mmHg (30–44 mmHg);
pO2, 132 mmHg (90–108 mmHg); and FiO2, 20%. However,
her erythropoietin was 1 mU/mL (normal reference range
for adults: 4–20 mU/mL).
On reviewing her past records from June 2011 to May
2015, her white blood cell (WBC) count was persistently
on the higher side (ranging from 11.77  109/L to
38.13  109/L), platelets were intermittently high (334–
649  109/L), and hemoglobin (Hb) level was intermittently
on the lower side due to menorrhagia (ranging from 6.8 g/dL
to 11.9 g/dL). She had consistent severe microcytic hypo-
chromic anemia. In November 2013, her complete blood
count parameters were as follows: Hb, 6.8 g/dL; mean cor-
puscular volume, 56.8 fL; mean corpuscular hemoglobin,
14.4 pg; and mean corpuscular hemoglobin concentration,
25.4 g/dL. Her iron studies revealed the following: iron,
8 lg/dL (normal: 28–170 lg/dL); total iron-binding capacity
(TIBC), 426 lg/dL (normal: 269–535 lg/dL); transferrin,
304 mg/dL (normal: 192–382 mg/dL); transferrin satura-
tion, 2% (normal: 15–60%); and ferritin, <1 ng/L (normal:
10–291 ng/mL).
On admission, the patient’s lactate dehydrogenase (LDH)
was 1112 U/L (normal range: 300–500 U/L). Abdominal
ultrasound showed a spleen size of 16  6  6 cm3. Chronic
myeloid leukemia was ruled out with negative bcr-abl. A
JAK2V617F mutation test was ordered, which was found to
be positive, and PV was diagnosed. In the hospital, her oral
iron therapy was discontinued and a therapeutic phle-
botomy was performed. She refused further phlebotomies
and was started on hydroxyurea 1500 mg daily.Table 1 Laboratory data revealed.
Complete blood count Result Reference range
Hemoglobin (g/dL) 20.6 11.5–16.0
Hematocrit (%) 64.6 32.0–45.0
RBC (M/lL) 7.6 4.00–5.506
Red cell width (%) 18.0 0–18.10
MCV (fL) 85.2 75.0–102.0
MCH (pg) 27.1 26.0–34.0
MCHC (g/dL) 31.9 30.5–36.0
WBC ( 109/L) 27.8 3.40–11.00
Platelets 399  109/L 130–400  109/L
Note. MCH = mean corpuscular hemoglobin; MCHC = mean cor-
puscular hemoglobin concentration; MCV = mean corpuscular
volume; RBC = red blood cell; WBC = white blood cell.
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The incidence of PV is 2.3/100,000 with a slightly higher
rate of occurrence in men than in women (1.2:1).1 The med-
ian age of diagnosis is 60 years. Polycythemia can be either
relative polycythemia or true polycythemia. Relative poly-
cythemia occurs due to a reduction in plasma volume
(e.g.: diuretic use, severe burns, vomiting, diarrhea, severe
dehydration, etc.). True polycythemia can be either pri-
mary or secondary. Primary polycythemia is one of the
chronic myeloproliferative disorders called as polycythemia
vera. Secondary polycythemia is due to excess erythropoi-
etin production in case of hypoxia, malignant conditions
(hepatocellular cancer, renal cell cancer, cerebellar
hemangioblastoma, and parathyroid carcinoma), uterine
leiomyoma, renal cyst, and meningioma.1
The symptoms of PV include pruritus (especially after hot
shower), headache, paresthesia, dizziness, visual distur-
bance, bleeding, and peptic ulcer disease.2 The vascular
complications in PV due to increased blood viscosity are
microvascular circulatory disturbances typical of thrombo-
cythemia including erythromelalgia, peripheral ischemia,
myocardial infarction, atypical cerebral ischemic attacks,
and major arterial and venous thrombotic events.3 The
life-threatening complications include cardiovascular com-
plications and progression to post-PV myelofibrosis or leuke-
mia. Approximately 12–21% of patients with PV develop
post-PV myelofibrosis, and approximately 7% develop leuke-
mia within 20 years.4 Polycythemia should be suspected
when there is an elevated level of hemoglobin or hematocrit
on normal oxygen saturation. However, as in the case dis-
cussed above, the finding can be masked in severe anemia.
Other common findings also include an elevated white blood
cell count, thrombocytosis, elevated lactate dehydroge-
nase, and splenomegaly. Serum erythropoietin is to be eval-
uated to differentiate between primary and secondary
polycythemia. Low erythropoietin is suggestive of PV, which
can be confirmed with a positive JAK2 mutation. The
JAK2V617F mutation is positive for around 95% of patients;
a further 2–4% of patients harbor mutations in JAK2 exon
12.5 Patients with low erythropoietin and negative
JAK2V617F should be screened for JAK2 exon 12 mutation.
Bone marrow biopsy reveals hypercellularity, an increased
number of megakaryocytes, giant megakaryocytes with
pleomorphism in megakaryocyte morphology, mild reticulin
fibrosis (in 12% of patients), and decreased bone marrow
iron stores.1 The World Health Organization diagnostic cri-
teria for PV include two major and three minor criteria.
The first major criterion is Hb >18.5 g/dL in men and
16.5 g/dL in women, or evidence of increased red cell vol-
ume (like increased hematocrit >99th percentile of
method-specific reference range for age, sex, and altitude
of residence). The second major criterion is a positive
JAK2V617F mutation or presence of functionally similar
mutations such as JAK2 exon 12 mutations. The minor crite-
ria include serum erythropoietin below the normal refer-
ence range; bone marrow biopsy showing hypercellularity
for age with trilineage growth with prominent erythroid,
granulocyte, and megakaryocyte proliferation; and endoge-
nous erythroid colony formation in vitro. The diagnosis of PV
requires the presence of two major criteria plus one minorasked due to severe iron deficiency anemia ..., Hematol Oncol Stem
Polycythemia vera masked due to iron deficiency anemia 3criterion, or the presence of the first major criterion plus
two minor criteria.
Since there is no proven drug that aims to completely
cure PV, the treatment is mainly focused on preventing
thrombotic events and its progression to PV myelofibrosis
and leukemia without increasing bleeding tendency. The
mainstay of treatment is phlebotomy, to keep the hemat-
ocrit level below 45%. Initially, chlorambucil, pipobroman,
and radioactive phosphorus were used to treat PV; however,
pipobroman and radioactive phosphorus were known to
increase the incidence of acute leukemia.6,7 Among the
cytoreductive agents, hydroxyurea is the first line of drug
recommended for controlling the proliferative phase of
PV. It is well tolerated and least toxic as compared with
the second-line drugs that include ruxolitinib, interferon,
and busulfan. In one of the trials, patients treated with rux-
olitinib, which is a Janus kinase 1/Janus kinase 2 inhibitor,
were found to have good hematocrit control without phle-
botomy and a decrease in spleen size.8 Interferon alpha
mainly acts by decreasing JAK2V617F mutation allele and
also helps in controlling severe pruritus, but the major
drawback is that it is highly toxic. Busulfan is reserved for
patients who do not respond to hydroxyurea due to its
potential side effects. The patients who fail to respond to
hydroxyurea have a 5.6-fold increase in mortality and a
6.8-fold increase in the risk of transformation to myelofibro-
sis or acute myeloid leukemia, and hence second-line drugs
are preferred despite their side effects.9 Low-dose aspirin is
recommended for prevention of thrombotic events if there
is no contraindication. Antihistamines are used to treat pru-
ritus. In a study, iron supplementation was recommended to
treat pruritus for patients who had iron deficiency in PV.10
Indiscriminate usage of iron is not recommended, as it
would progressively increase the red cell mass. Apart from
symptomatic management of PV, other measures to prevent
thrombosis and bleeding are to treat existing conditions
such as hypertension, diabetes, hyperlipidemia, and hyper-
cholesterolemia; avoid oral contraception and smoking;
adopt healthy lifestyle modifications. The median survival
of treated patients is 13 years or more and that of untreated
patients ranges between 6 months and 18 months from diag-
nosis.11 However, factors such as age >70 years, white blood
count >13 k/lL, and thromboembolism at the time of diag-
nosis were considered as independent risk factors for
survival.12
Very few patients present with actual symptoms, and
most are diagnosed on routine laboratory investigation. In
our patient, the diagnosis was masked due to severe anemia
in the past, although she had elevated white cell and plate-
let counts in the past. Her hemoglobin level started increas-
ing only after she became amenorrheic and was placed on
iron replacement. An early diagnosis could have been possi-
ble if her elevated white cell count was considered as a dif-Please cite this article in press as: Kambali S, Taj A, Polycythemia vera m
Cell Ther (2016), http://dx.doi.org/10.1016/j.hemonc.2016.08.007ferential diagnosis of a myeloproliferative disorder after
ruling out infection with negative culture.
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